Clinical Trials: Multiple Sclerosis

Alabama

Cullman; North Central Neurology Associates, P.C.
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Arizona

Pheonix; Neuro-Immunology Program
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Phoenix; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Phoenix; Research Site
New Oral Investigational Treatment for Relapsing-Remitting Multiple Sclerosis

Tucson; Northwest NeuroSpecialists
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Tucson; Northwest NeuroSpecialists, PLLC
Clinical Research Study Available for People Diagnosed with Multiple Sclerosis

Tucson; Northwest NeuroSpecialists, PLLC
Multiple Sclerosis Study

California

La Jolla; Coordinated Clinical Research (La Jolla, CA)
Have you been diagnosed with Multiple Sclerosis? A clinical research study for Relapsing-Remitting MS is underway in your area.

San Francisco; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Colorado

Boulder; Alpine Clinical Research Center
Quality of Life study for patients with relapsing forms of Multiple Sclerosis who are transitioning from Rebif to Rebif-New Formulation

Boulder; Alpine Clinical Research Center
Combination Rebif and Oral Cladribine Therapy for Multiple Sclerosis

Centennial; 1st International Clinical Research Center
Do you have Relapsing Remitting Multiple Sclerosis?

Centennial; Research Site
New Oral Investigational Treatment for Relapsing-Remitting Multiple Sclerosis

Fort Collins; Research Site
New Oral Investigational Treatment for Relapsing-Remitting Multiple Sclerosis

Connecticut

New Haven; Research Site
New Oral Investigational Treatment for Relapsing-Remitting Multiple Sclerosis

New Haven; Yale Center for MS Treatment and Research
Do you have relapsing-remitting or secondary-progressive multiple sclerosis?

Salisbury; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Florida

Bradenton; Bradenton Research
Bradenton Neurology, Inc. is participating in a nationwide research study for individuals who have been diagnosed with Multiple Sclerosis.

Gainesville; Florida Medical Research Institute
MULTIPLE SCLEROSIS?

Orlando; Research Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Sarasota; The Roskamp Institute, Clinical Trials Division
Phase III study comparing different doses of study drug with placebo for Relapsing Remitting Multiple Sclerosis (RRMS)

Sarasota; The Roskamp Institute, Clinical Trials Division
Phase III study for patients with Relapsing remitting Multiple Sclerosis

Sarasota; The Roskamp Institute, Clinical Trials Division
Do you or a loved one have relapsing remitting multiple sclerosis?

Sarasota; Lovelace Scientific Resources - Sarasota
Multiple Sclerosis

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Vero Beach; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Georgia

Atlanta; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Atlanta; MS Center of Atlanta
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Illinois

Chicago; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Northbrook; Research Site
New Oral Investigational Treatment for Relapsing-Remitting Multiple Sclerosis

Northbrook; Research Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Indiana

Fort Wayne; Research Site
New Oral Investigational Treatment for Relapsing-Remitting Multiple Sclerosis

Ft. Wayne; Fort Wayne Neurological Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Indianapolis; University of Indiana
Do you have relapsing-remitting or secondary-progressive multiple sclerosis?

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Iowa

Des Moines; Research Site
New Oral Investigational Treatment for Relapsing-Remitting Multiple Sclerosis

Kansas

Kansas City; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Kansas City; Research Site
New Oral Investigational Treatment for Relapsing-Remitting Multiple Sclerosis

Kansas City; Landon Center / Neurology
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Kansas City; University of Kansas Medical Center
Do you have relapsing-remitting or secondary-progressive multiple sclerosis?

Lenexa; MidAmerica Neuroscience Institute
Relapsing forms of Multiple Sclerosis study to evaluate the safety and tolerability of two doses of an oral study drug over 24 weeks (study 7)

Lenexa; Research Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Kentucky

Lexington; Department of Neurology University of Kentucky College of Medicine
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Lexington; Research Site
New Oral Investigational Treatment for Relapsing-Remitting Multiple Sclerosis

Louisville; Kentucky Neuroscience Research
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Maryland

Baltimore; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Baltimore; University of Maryland
Do you have relapsing-remitting or secondary-progressive multiple sclerosis?

Bismarck; Odyssey Research Services
A Multiple Sclerosis Research Study

Massachusetts

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Michigan

Ann Arbor; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Farmington Hills; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Farmington Hills; Research Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Milwaukee; Center for Neurological Disorders
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Minnesota

Minneapolis; Research Site
New Oral Investigational Treatment for Relapsing-Remitting Multiple Sclerosis

Mississippi

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Missouri

St. Louis; Research Site
New Oral Investigational Treatment for Relapsing-Remitting Multiple Sclerosis

Nevada

Las Vegas; University of Nevada School of Medicine
Participants needed for a research study in Multiple Sclerosis

New Hampshire

Lebanon; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

New Mexico

Albuquerque; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

New York

Albany; Upstate Clinical Research, LLC
A Double-Blind, Placebo Controlled Multi-Center Study To Evaluate The Efficacy And Safety of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis

Mineola; Winthrop University Hospital Clinical Trials Center
Relapsing remitting multiple sclerosis

Mineola; Winthrop University Hospital Clinical Trials Center
Volunteers needed for a multiple sclerosis research study

Mineola; Winthrop University Hospital Clinical Trials Center
Volunteers needed for a multiple sclerosis research study

New York; Biomedical Research Alliance of New York
Relapsing Remitting Multiple Sclerosis (RRMS)

New York; Mount Sinai Medical Center
OMEGA-Oral Megadose Corticosteroid Therapy of Acute Exacerbations in Multiple Sclerosis

New York; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

New York; Mount Sinai Medical Center
A 24-month, double-blind, randomized, multi-center, placebo-controlled, parallel-group study comparing the efficacy and safety of FTY720 1.25mg and 0.5mg administered once daily versus placebo in patients with relapsing remitting multiple sclerosis

New York; Mount Sinai Medical Center
A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Rituximab in Adults with Primary Progressive Multiple Sclerosis PROTOCOL: U2786g

New York; Mount Sinai Medical Center
A 21 WEEK STUDY TO EVALUATE SAFETY AND EFFICACY OF ORAL FAMPRIDINE-SR IN SUBJECTS WITH MULTIPLE SCLEROSIS.

New York; Mount Sinai Medical Center
A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon beta 1-a and Glatiramer Acetate to Either Agent Alone in Patients with Relapsing-Remitting Multiple Sclerosis (CombiRx Phase III)

New York; Mount Sinai Medical Center
ITN020AI: A Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Atorvastatin in Patient with Clinically Isolated Syndrome and High Risk of Conversion to Multiple Sclerosis (MS) (STAYCIS)

New York; Mount Sinai Medical Center
The Establishment of a Patient Registry and Initiation of Related Projects of the New York State Multiple Sclerois Consortium

New York; Biomedical Research Alliance of New York
Relapsing - Remitting Multiple Sclerosis (RRMS)

New York; Biomedical Research Alliance of New York
Multiple Sclerosis treated with Betaseron® - Adults

New York; Biomedical Research Alliance of New York
Secondary Progressive Multiple Sclerosis - Adults

Plainview; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Rochester; Research Site
New Oral Investigational Treatment for Relapsing-Remitting Multiple Sclerosis

Schenectady; Schenectady Neurological Consultants, PC
The TYSABRI Global Observational Program in Safety (TYGRIS) is a safety observational cohort study designed to obtain long-term safety data in multiple sclerosis (MS) patients treated with TYSABRI in a clinical practice setting.

Stony Brook; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

North Carolina

Charlotte; Research Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Salisbury; Central Carolina Neurology & Sleep, PA
Looking for MS Patients for a Quality of Life Study

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Winston-Salem; Research Site
New Oral Investigational Treatment for Relapsing-Remitting Multiple Sclerosis

North Dakota

Fargo; Research Site
New Oral Investigational Treatment for Relapsing-Remitting Multiple Sclerosis

Ohio

Cleveland; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Columbus; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Columbus; Research Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Dayton; Research Site
New Oral Investigational Treatment for Relapsing-Remitting Multiple Sclerosis

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Oklahoma

Oklahoma City; Research Site
New Oral Investigational Treatment for Relapsing-Remitting Multiple Sclerosis

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Oregon

Portland; Oregon Health & Science University
Do you have relapsing-remitting or secondary-progressive multiple sclerosis?

Tualatin; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Pennsylvania

Hershey; Research Site
New Oral Investigational Treatment for Relapsing-Remitting Multiple Sclerosis

Philadelphia; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Philadelphia; Research Site
New Oral Investigational Treatment for Relapsing-Remitting Multiple Sclerosis

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Rhode Island

Providence; The Neurology Foundation,Inc.
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

South Carolina

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Tennessee

Franklin; Research Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Nashville; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Nashville; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Texas

Houston; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Lubbock; Research Site
New Oral Investigational Treatment for Relapsing-Remitting Multiple Sclerosis

Round Rock ; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

San Antonio; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

San Antonio; Research Site
New Oral Investigational Treatment for Relapsing-Remitting Multiple Sclerosis

Vermont

Burlington; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Virginia

Charlottesville; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Washington

Kirkland; MS Center Evergreen
Do you have relapsing-remitting or secondary-progressive multiple sclerosis?

Maitland; MS Center at Evergreen Healthcare
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Mountlake Terrace; Integrity Medical Research, LLC
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

Washington, DC

Washington; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Washington; Research Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

West Virginia

Charleston; Research Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Charleston; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Wisconsin

Milwaukee; Research Site
New Oral Investigational Treatment for Relapsing-Remitting Multiple Sclerosis

Milwaukee; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

International

Edegem, Belgium; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Sijsele-Damme, Belgium; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Sofia, Bulgaria; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Toronto, ON, Canada; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Vancouver, BC, Canada; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Ostrava, Czech Republic; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Pardubice, Czech Republic; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Prague, Czech Republic; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Praha, Czech Republic; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Teplice, Czech Republic; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Arhus, Denmark; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Sonderborg, Denmark; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Helsinki, Finland; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Turku, Finland; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Bordeaux, France; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Caen Cedex 9, France; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Clermont-Ferrand Cedex1, France; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Lyon, France; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Montpellier Cedex, France; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Berlin, Germany; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Hamburg, Germany; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Marburg, Germany; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Regensburg, Germany; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Siegen, Germany; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Tübingen, Germany; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Ulm, Germany; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Budapest, Hungary; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Budapest, Hungary; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Gyor, Hungary; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Milan, Italy; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Roma, Italy; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Breda, Netherlands; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Breda, Netherlands; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Nieuwegein, Netherlands; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Nijmegen, Netherlands; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Gdansk, Poland; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Lodz, Poland; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Lublin, Poland; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Warszawa, Poland; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Bucuresti, Romania; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Targu Mures, Romania; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Ekaterinburg, Russian Federation; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Kazan, Russian Federation; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Moscow, Russian Federation; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Nizhny Novgorod, Russian Federation; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Novosibirsk, Russian Federation; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Tyumen, Russian Federation; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Banska Bystrica, Slovakia; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Bratislava, Slovakia; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Kosice, Slovakia; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Nitra, Slovakia; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Barcelona, Spain; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Madrid, Spain; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Malaga, Spain; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Oviedo, Spain; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Sevilla, Spain; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Valencia, Spain; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Basel, Switzerland; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Lausanne, Switzerland; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Zurich, Switzerland; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Kharkov, Ukraine; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Kiev, Ukraine; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Propetrovsk, Ukraine; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Vinnytsya, Ukraine; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Liverpool, United Kingdom; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Newcastle, United Kingdom; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Newcastle upon Tyne, United Kingdom; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Nottingham, United Kingdom; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Sheffield, United Kingdom; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Sheffield, United Kingdom; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323